Clin2
NCT07233239Possibly a fitRecruiting

CBD liquid for focal epilepsy seizures

Focal Seizures

Part of Brain & nervous system clinical trials.

This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
12 years to 75 years
Study type
Interventional

Who can take part

  • You are between 12 and 75 years old.
  • You have been diagnosed with focal epilepsy (seizures that start in one area of the brain).
  • You are currently taking 1 to 4 seizure medications that have been stable.
  • You are not currently using Epidiolex, medical cannabis, or any CBD products.
  • You do not have a history of suicidal behavior or current suicidal thoughts.
  • You do not have another serious unstable medical condition besides epilepsy.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06132893Recruiting· Phase 2/Phase 3
Testing BHV-7000 for hard-to-control focal seizures in adults

This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.

Phoenix, Arizona
NCT07668856Recruiting· Phase 3
CBD for children with hard-to-treat epilepsy

This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.

Utrecht, Utrecht
NCT07723976Not yet recruiting· Phase 3
Testing CBD oil for seizures in developmental and epileptic encephalopathy

This study tests a new CBD oil (CBD-OS) to see if it safely reduces seizures in people with developmental and epileptic encephalopathy (DEE), a condition where both development and seizure control are affected. Participants must already be on a stable antiseizure treatment.

NCT05716100Recruiting· Phase 3
Study drug for focal epilepsy that isn’t controlled on current meds

This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.

Little Rock, Arkansas
NCT06612775Not yet recruiting· Phase 2
Testing CB03-154 for adults with focal epilepsy

This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.

NCT07023744Not yet recruiting· Phase 2
Cannabinoids for drug-resistant epilepsy in adults and children

This trial tests if cannabinoids can help people who still have seizures despite trying two or more standard seizure medications. It aims to reduce seizure frequency in those with drug-resistant epilepsy.

Hear when a new Focal Seizures trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.